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Graphical Abstract. Upper diagram- The red and black symbols on the histone tails 
represent the respective chromatin-activating and -repressor marks. Stemmed stars 
represent DNA methylation marks. Blue wavy lines depict gene transcripts (RNAs). 
The rejuvenated brain on the right is shown in blue color.  Lower diagram- On the left, 
the cells of origin are in brown color, in the center, pluripotent intermediates are 
displayed in blue and on the right, rejuvenated cells are displayed in blue whereas 
nonrejuvenated cells are represented in brown.    
 
 
 
HIGHLIGHTS 
 Brain aging is associated with an increase in neurodegenerative pathologies. 
 López-León et al., 2017  3 
 
  Regenerative medicine offers novel approaches for the treatment of these 
pathologies. 
 Generation of neural cells for treating the aging brain is of clinical interest.  
 Direct reprogramming paradigms to generate neural cells are particularly 
relevant. 
 Rejuvenation by cell reprogramming promises revolutionary therapies for the 
brain. 
 
ABSTRACT 
Aging is associated with a progressive increase in the incidence of neurodegenerative  
diseases, with Alzheimer’s (AD) and Parkinson's (PD) disease being the most 
conspicuous examples. Within this context, the absence of efficacious therapies for 
most age-related brain pathologies has increased the interest in regenerative medicine. 
In particular, cell reprogramming technologies have ushered in the era of personalized 
therapies that not only show a significant potential for the treatment of 
neurodegenerative diseases but also promise to make biological rejuvenation feasible. 
We will first review recent evidence supporting the emerging view that aging is a 
reversible epigenetic phenomenon. Next, we will describe novel reprogramming 
approaches that overcome some of the intrinsic limitations of conventional induced–
pluripotent-stem-cell technology. One of the alternative approaches, lineage 
reprogramming, consists of the direct conversion of one adult cell type into another by 
transgenic expression of multiple lineage-specific transcription factors (TF). Another 
strategy, termed pluripotency factor-mediated direct reprogramming, uses universal TF 
to generate epigenetically unstable intermediates able to differentiate into somatic cell 
types in response to specific differentiation factors.  In the third part we will review 
studies showing the potential relevance of the above approaches for the treatment of AD 
and PD.  
(194 words) 
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1. AGE-RELATED NEURODEGENERATIVE DISEASES  
Aging is associated with cognitive decline and a progressive increase in the incidence of 
neurodegenerative diseases. In the central nervous system (CNS), dopaminergic (DA) 
and cholinergic neurons are among the most susceptible cells to the deleterious effects 
of aging (Grothr et al., 2011; Fischer et al., 1992; de Rijk et al., 1995). Thus, the 
basal forebrain cholinergic system undergoes mild neurodegenerative changes during 
normal aging as well as severe atrophy in Alzheimer´s Disease (AD), the most common 
form of neurodegeneration and dementia among older people. In fact, the cholinergic 
degeneration in AD appears to take place against a background of age-associated 
atrophy and the exacerbated degeneration occurring can be detected at very early stages 
of cognitive impairment (Grothr et al., 2011). In rats, aging is paralleled by 
degenerative and/or atrophic changes in the forebrain cholinergic system and these 
morphologic changes are associated with a decline in spatial learning ability (Fischer et 
al., 1992). 
Parkinson's disease (PD) is a neurological disorder associated with degeneration and 
progressive loss of DA neurons in the midbrain substantia nigra, which leads to a 
profound reduction of dopamine levels in the striatum (Gaillard and Jaber, 2011). 
When 50-60% of the nigral DA neurons have degenerated and 70-80% of DA terminals 
in the striatum have been depleted, motor symptoms -like resting tremor, muscular 
rigidity, bradykinesia and postural instability- become evident (Bernheimer et al., 
1973). PD affects 0.3-1.0% of the human population and is the most conspicuous 
reflection of the vulnerability of DA neurons to aging, the only unequivocal risk factor 
for PD (de Rijk et al., 1995). In rats, aging is associated with a progressive 
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degeneration and loss of a different group of central DA neurons, namely, the 
hypothalamic tuberoinfundibular dopaminergic (TIDA) neurons, whose physiologic 
role is to exert a tonic inhibitory control of prolactin secretion and lactotropic cell 
proliferation in the anterior pituitary gland (Sarkar et al., 1982). Progressive 
dysfunction and loss of TIDA neurons during normal aging in the female rat is 
paralleled by chronic hyperprolactinemia (Goya et al., 1990) and the development of 
pituitary prolactinomas (Cónsole et al., 1997). Although aging rats do not display 
parkinsonian symptoms even at advanced ages (32 months), they lose 35-40% of the 
nigral DA neurons and show a marked deficit in motor performance (Sánchez et al., 
2008). In humans, normal aging is also associated with a progressive decline in motor 
performance and a gradual loss of nigral DA neurons (Rudow et al., 2008). Therefore, 
progressive deterioration of cognitive function and gradual decline in central DA 
activity seem to represent basic features of normal aging in both laboratory rodents and 
humans. Exacerbation of these processes would lead to AD and PD, respectively. 
Within this context, cell reprogramming emerges as a powerful technology that 
promises to make possible the implementation of personalized regenerative medicine 
aimed at preventing or delaying the progression of AD and PD. Furthermore, the 
recently emerging evidence that partial cell reprogramming may be capable of 
rejuvenating old animals (Ocampo et al., 2016b) brings about the promise of achieving, 
perhaps in the not-too-distant future, the ultimate cure for age-related brain (and other) 
disorders, rejuvenation. We will begin by reviewing this fascinating new avenue of 
regenerative medicine.   
 
2. REJUVENATION BY CELL REPROGRAMMING 
2.1 The Road to Cell Reprogramming 
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The generation of induced pluripotent stem cells (iPSCs) from somatic cells has 
demonstrated that somatic mammalian cells from adult individuals can be 
reprogrammed to a pluripotent state by overexpression of a small number of embryonic 
transcription factors (TF) (Takahashi and Yamanaka, 2006). The achievement of 
induced pluripotency constitutes the synthesis of scientific advances and technologies 
that were developed over the last six decades. Among the pioneering efforts that paved 
the path to cell reprogramming, the work of John Gurdon and collaborators in the sixties 
should be mentioned. Their seminal studies in frogs demonstrated that animal cloning is 
possible (Gurdon 1962; Gurdon 2006). Mammalian cloning by somatic cell nuclear 
transfer (SCNT), was achieved in 1996 with the birth of Dolly, the sheep (Wilmut et 
al., 1997). In the 1980s, it was discovered that a single TF, MYOD, can convert 
fibroblasts into skeletal muscle cells demonstrating that cell fate can be changed 
through the overexpression of specific TF (Davis et al., 1987; Choi et al., 1990; 
Weintraub et al., 1989). These findings challenged the fundamental doctrine that 
terminally differentiated cells are irreversibly determined in their specialization. The 
discovery of animal cloning strongly suggested that the somatic cell genome is 
remarkably plastic. Another transcendent implication of the cloning experiments was 
that in the cytoplasm of a mature oocyte there are molecules capable of reprogramming 
a somatic nucleus, setting in motion the developmental program for a new individual. 
The identity of the above molecules began to emerge in 2006, when Takahashi and 
Yamanaka demonstrated that the transfer of the four pluripotency genes oct4, klf4, sox2 
and c-myc (OKSM genes), to mouse fibroblasts can reprogram them, taking the cells to 
a stage (the iPSC stage) in which they behave as embryonic stem cells (ESCs) 
(Takahashi and Yamanaka, 2006). These discoveries have opened a panorama of 
unimagined possibilities for the development of personalized therapeutic approaches 
(Bayart and Cohen-Haguenauer, 2013; Nedelec et al., 2013). 
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2.2 Aging and Epigenetics: the Promise of Rejuvenation by Cell Reprogramming 
In light of a growing body of reports demonstrating that reprogramming of somatic cells 
from aged individuals rejuvenates them to their embryonic stage (a topic to be reviewed 
briefly below), the emerging view is that aging is a reversible epigenetic phenomenon 
where age-related DNA damage seems to play no significant role (Rando et al., 2012; 
Ocampo et al., 2016a; López León & Goya, 2017).  
Studies in model organisms like yeasts, worms and flies have shown that aging is 
associated with progressive changes in chromatin regulation. In young cells the genome 
is in a relatively high level of repression that is in part achieved by DNA methylation 
and relatively high levels of histone H3 trimethylated at lysine 9 (H3K9me3) and at 
lysine 27 (H3K27me3) and histone H4 trimethylated at lysine 20 (H4K20me3), all of 
which are associated with transcriptionally repressed chromatin, as well as relatively 
low levels of histone H3 trimethylated at lysine 4 (H3K4me3) and  histone H4 
acetylated at lysine 16 (H4K16ac), both of which are associated with active chromatin. 
Aging seems to be associated with a progressive derepression of the transcriptional 
activity of chromatin, which is effected in part by reduction in DNA methylation 
(although paradoxically, DNA of specific gene groups becomes hypermethylated at 
CpGi), decrease of epigenetic repressor marks like H3K9me3, H3K27me3 and 
H4K20me3 as well as an increase in the levels of activation marks like H3K4me3 and 
H4K16ac (Fig.1, upper scheme). Acetylation and methylation of this group of histones 
is specifically achieved by a number of protein groups associated with chromatin, like 
the histone methyl transferases and histone demethylases, histone deacetylases 
(including sirtuins), the polycomb complex, trithorax groups and others. A detailed 
description of the mechanisms involved in altering the epigenetic state of chromatin 
during aging is beyond the scope of this review and the reader is referred to a number of 
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comprehensive reviews (Greer et al., 2010; Han and Brunet, 2012; Benayoun et al., 
2015; Sen et al., 2016). These epigenetic marks are influenced by both endogenous 
(e.g., hormones) and exogenous (e.g., nutrition) environmental factors (Sen et al., 
2016).  
A cluster of recent studies (see below) strongly suggests that when cells from old 
individuals are reprogrammed to the iPSC stage many, if not all epigenetic marks of 
aging are erased (Fig. 1, lower scheme). Furthermore, if iPSCs derived from aged 
individuals are re-differentiated to the original cell type, the rejuvenated cells display 
the structural and functional features of young wild-type counterparts. Thus, it has been 
shown that reprogramming skin fibroblasts from aged humans to the iPSC stage and 
differentiating them to induced neurons (i.e., iPSC-derived neurons) rejuvenates their 
transcriptome signature and their nucleocytoplasmic compartmentalization (NCC) 
making them comparable to that of wild-type fibroblasts from young donors (Mertens 
et al., 2015). Induced neurons (iNs) were also generated by transdifferentiation, a 
process that bypasses the pluripotency stage. Transdifferentiated iNs retain the 
transcriptome profile of old fibroblasts and showed a disrupted NCC as old fibroblasts 
do (Mertens et al., 2015). The authors conclude that dedifferentiation to the 
pluripotency stage is necessary to fully erase all marks of aging in the epigenome. In 
another study, skin fibroblasts from old and centenarian normal human donors were 
dedifferentiated to the iPSC stage and redifferentiated back into fibroblasts. In the 
rejuvenated fibroblasts it was found that the telomere length was restored and that gene 
expression profiles, oxidative stress levels and mitochondrial metabolism was found to 
be comparable to that of fibroblasts from young humans (Lapasset et al., 2011). In an 
interesting study with skin fibroblasts from healthy old humans, it was observed that the 
lower oxygen consumption typically observed in the mitochondria of cells from old 
individuals was restored to youthful levels after the old cells were dedifferentiated to 
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iPSCs and differentiated back to rejuvenated fibroblasts. The damage in mitochondrial 
DNA was comparable in fibroblasts from young donors and rejuvenated fibroblasts 
from old donors. It was also found that in the old fibroblasts there was no damage to the 
nuclear GCAT gene which encodes an enzyme involved in the synthesis of glycine; 
rather, the gene was epigenetically down regulated in those old cells. Rejuvenation 
reversed this repression and restored normal glycine levels in the mitochondria of 
rejuvenated fibroblasts (Hashizume et al., 2015). In another study, it was reported that 
overexpression of the pluripotency factor NANOG in senescent or progeroid myogenic 
progenitors reversed cellular aging and fully restored the ability to generate contractile 
force. This transformation was mediated by the reactivation of the Rho-associated–
protein-kinase (ROCK) and the transforming-growth-factor-ß (TGF-β) pathways 
(Mistriotis et al., 2017).   
Rejuvenation by cell reprogramming is one of the new horizons opened by iPSC 
technology. A particularly promising report appeared recently (Ocampo et al., 2016b), 
showing that cyclic partial reprogramming in transgenic progeric mice carrying a Tet-
On regulatable cassette harboring the four Yamanaka pluripotency, genes whose 
expression is activated in cycles consisting of a two-day period of transgene 
overexpression (effected by administration of the antibiotic doxycycline (DOX) via the 
drinking water) followed by a 5-day period or repression (effected by DOX removal), 
can prolong their survival time. Analysis of internal organs revealed that many signs of 
senescence disappeared in adult (senile) mice after a few cycles of partial 
reprogramming (Ocampo et al., 2016b). At the time of this writing this is, to our 
knowledge, the first report showing that in vivo rejuvenation can be achieved by a 
partial reprogramming approach (Fig. 1, lower scheme). Although the authors do not 
report an assessment of the brains of the rejuvenated animals, it seems likely that some 
aging markers may have been attenuated in their brain. It is reasonable to expect that 
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there will be numerous follow-up in vivo studies using cell reprogramming to achieve in 
vivo rejuvenation, an expectation that bears the implication that this approach will be 
tried in animal models of neurodegenerative diseases. Considering the ever-accelerating 
rate of cell reprogramming research, there is a clear promise that in the not-too-distant 
future reprogramming-based medical technologies will be developed not only to treat so 
far incurable age-related brain diseases like AD and PD but also to reverse the 
functional declines (like memory impairment) that occur in the human brain during 
normal aging.     
 
3. TOWARDS iPSC-FREE CELL REPROGRAMMING STRATEGIES 
The first cell reprogramming strategy mediated by iPSC was the one developed by the 
Yamanaka's group whose approach, as mentioned above, involves converting a somatic 
cell line into iPSCs, which subsequently can be re-differentiated to specific somatic cell 
types of interest. This method is still the most widely used strategy to convert a somatic 
cell type into another and is the only procedure so far used to rejuvenate cells and 
animals (cf., section 2.2 above). Since its discovery in 2006, iPSC technology has been 
extensively characterized - for instance, it has been demonstrated that cellular origin 
influences the in vitro differentiation potentials of iPSCs into embryoid bodies and 
different cell types. However, it is also known that continuous passaging of iPSCs 
largely attenuates these differences (Polo et al., 2010). High fidelity protocols to 
differentiate iPSC into neural cells that closely resemble their endogenous counterparts 
have been developed. Thus, it was recently reported that iPSC-derived cortical neurons 
from myoclonus-dystonia (M-D) patients with mutations (W100G and R102X) in the 
maternally imprinted ε-sarcoglycan (SGCE) gene were generated and properties such as 
imprinting, mRNA and protein expression were analyzed. Comparison of the promoter 
during reprogramming and differentiation demonstrated a tissue-independent 
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differential methylation. DNA sequencing with methylation-specific primers and cDNA 
analysis in patient neurons indicated selective expression of the mutated paternal SGCE 
allele. A phenotypic characterization of the neurons showed the suitability of iPSC-
derived cortical neurons with SGCE mutations for M-D research and, in more general 
terms, encouraged the use of iPSC-derived cellular models to study epigenetic 
mechanisms impacting on health and disease (Grütz et al., 2017). In another instance of 
an improved protocol for generation of iPSC-derived neurons, a fully defined feeder- 
and xenogeneic-free protocol for the generation of ventral midbrain dopamine (vmDA) 
neurons from human pluripotent stem cells (hPSCs) has been recently reported (Niclis 
et al., 2017) (c.f., section 5.1 for further details). 
Despite the advantages of iPSC technology, the procedure as a whole is arduous, 
lengthy and costly. Since the protocols to generate iPSCs comprise a number of steps, 
the efficiency with which the final cell type is generated may be low. Furthermore, a 
number of concerns about safety of iPSC-derived cells need to be addressed before 
these cells can be used clinically (Okano et al., 2013). It is important to note that a 
commonly used assay for demonstrating pluripotency is the capacity to forming 
teratomas (Patel and Yang, 2010). Therefore, the tumorigenic potential of 
contaminating iPSCs that fail to differentiate increases the risk for any clinical 
application of somatic cells generated by this procedure (Miura et al., 2009). These 
hurdles have led to the emergence of other ways of reprogramming cells that involve 
direct conversion between cell types. These strategies are outlined below and illustrated 
in Figure 2. 
3.1 Lineage Reprogramming 
An alternative cell reprogramming approach, known as lineage reprogramming (LR) 
or transdifferentiation, emerged in 1987 (Davis et al.) for the generation of specific cell 
types. This method consists of the direct conversion of one somatic cell type into 
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another one by ectopic expression of multiple lineage-specific TF  or microRNAs 
(miRNA) without the cell passing through the pluripotent stem cell stage (Ieda et al., 
2013; Sancho-Martinez et al., 2012). This strategy uses factors that show specific 
expression in target cells. Thus, the adenoviral-mediated gene transfer of a combination 
of three TF was able to reprogram efficiently pancreatic exocrine cells into functional β 
cells in mice, which constituted the first documented evidence of cell reprogramming in 
vivo by defined factors (Zhou et al., 2008). A number of studies have demonstrated that 
LR can yield a diverse range of medically relevant cell types, such as cardiomyocytes 
and neurons (Ieda et al., 2010; Kim et al., 2011a; Vierbuchen et al., 2010). The 
transdifferentiated cells exhibit a functionality equivalent to that of the cells 
differentiated from iPSCs or their wild-type counterparts and show no tumorigenicity 
when transplanted in vivo (Liu et al., 2012a; Matsui et al., 2012). However, cells 
generated by this procedure may demonstrate residual memory of cells of origin and 
identity differences as well as  restricted proliferative potential, limited cell type 
diversity and even senescence (Margariti et al., 2012), which may in turn substantially 
compromise their potential application in regenerative therapy. Furthermore, when LR 
is applied to somatic cells from old donors to generate neural cells, the induced neurons 
will retain the age-related features of the donors (Mertens et al., 2015), which 
represents an additional limitation for their use in cell therapy. Despite these limitations, 
particularly the lack of rejuvenation in neural cells derived by LR, in the following 
sections we include in vitro and in vivo reports documenting the application of induced 
neural cells generated by LR to models of PD and AD as we consider that the results 
achieved should be known by the readers.   
3.2 Pluripotency factor-mediated Direct Reprogramming 
Another approach to regenerative medicine, termed direct reprogramming or 
pluripotency-factor-mediated direct reprogramming (PDR) has also emerged (Kim 
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et al., 2012). This procedure uses fully differentiated somatic cells and converts them 
into other somatic cell types by transient expression of pluripotency genes, usually for 3 
to 5 days, thus generating epigenetically unstable (EU) intermediates which are 
responsive to appropriate cocktails of specific differentiation factors (Kim et al., 2011b;  
Efe et al., 2011; Ma et al., 2013).  
The PDR strategy originated from initial observations indicating that iPSCs are 
generated in either a sequential or stochastic manner (Stadtfeld et al., 2008; 
Brambrink et al., 2008; Hanna et al., 2009). This led Kim et al. (2012) to hypothesize 
that it could be possible to manipulate cells at an early, epigenetically highly unstable 
state, induced by the Yamanaka pluripotency factors. In the presence of appropriate 
differentiation factors, these EU intermediates can be subsequently induced to 
differentiate into various somatic cell lineages with more stable epigenetic profiles 
(Artyomov et al., 2010). This new method has several advantages such as the use of a 
universal pluripotency gene set and the ability to generate rejuvenated multipotent 
progenitor cell populations capable to differentiate into various tissue-specific 
destination cells under specific conditions (Kim et al., 2012; Kim et al., 2011b; Efe et 
al., 2011). 
Although the initial thinking was that in PDR the EU intermediates bypassed the 
pluripotency state (Kim et al., 2012), subsequent studies showed that when PDR is used 
to generate reprogrammed cardiomyocytes or neural stem cells (NSC), most of the 
induced cells derived from mouse fibroblasts by OSKM-induced conversion pass 
through a transient pluripotency state as evidenced by the reactivation of the X 
chromosome and expression of endogenous NANOG and OCT4 (Maza et al., 2015). 
The evidence that EU intermediates pass through a transient pluripotency state, has been 
further strengthened by a study showing that when PDR is used to generate induced 
neural stem cells (iNSCs) from mouse fibroblasts, iNSC colonies repress retroviral 
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transgenes and reactivate silenced X chromosomes, both of which are hallmarks of 
pluripotency (Bar-Nur et al., 2015). In view of this evidence we now consider the 
terms UE intermediates and pluripotent intermediates to be interchangeable.The fact 
that PDR involves a transient pluripotency stage makes it conceivable that unlike LR, 
PDR applied to somatic cells from old donors may erase at least part of the epigenetic 
marks of aging. This hypothesis is supported by a report cited above documenting that 
transient overexpression of the OSKM genes not only can rejuvenate somatic cells from 
progeric mice but is even able to rejuvenate the progeric mice themselves, increasing 
their survival time (Ocampo et al., 2016b).       
Lineage reprogramming and PDR share in common a direct conversion from one cell 
type into another relying on specific signals to help the original cells reach the desired 
cell-type destination and both are patient-specific. In contrast to lengthy iPSC-mediated 
cell reprogramming, in the direct approaches the conversion usually occurs in a short 
period of time and the induced cells have no tumorigenic potential. A significant 
difference between PDR and LR is that the former generates multipotent precursor cells 
whereas the later drives the somatic cells of origin directly to terminal cells (Prasad et 
al., 2016).  
 
4. GENERATION OF NEURAL CELLS BY LR AND PDR 
There is a keen interest in reprogramming somatic cells to mature neurons and neural 
precursors, which can later be used for implementing cell therapy for neurodegenerative 
pathologies like AD and PD. This section will review PDR and LR procedures used to 
generate them, leaving for later sections on specific brain pathologies the reviewing of 
procedures to obtain specific neuronal cell subtypes like DA neurons. 
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It has been demonstrated that nonneural somatic cells can be transdifferentiated into 
functional neurons by lineage-determining TF (Kim et al., 2011a). Initially, mouse 
(Vierbuchen et al., 2010) and human (Pang et al., 2011; Ambasudhan et al., 2011) 
fibroblasts were efficiently converted into functional neurons in vitro by transfer of the 
genes for some neuronal lineage-specific TF and/or miRNA, under precisely defined 
conditions. Embryonic and postnatal mouse fibroblasts could give rise to iNs by 
transferring only three neuronal-specific TF, namely BRN2 (encoded by POU3F2), 
achaete-scute homologue 1 (ASCL1) and myelin TF 1-like protein (MYT1L), a cocktail 
known as BAM (Vierbuchen et al., 2010). The resulting iNs display typical neural 
morphologies and express multiple neural markers. When human fibroblasts are 
combined with the TF neurodifferentiation D1 (NEUROD1), BAM can convert human 
fibroblasts into iNs, which are also able to generate action potentials and form 
functional synapses with murine cortical neurons in coculture (Pang et al., 2011). 
Shortly after this discovery, a number of groups reported successful generation of iNs 
from human fibroblasts (Ambasudhan et al., 2011: Pfisterer et al., 2011). These 
findings clearly show that the overexpression of a limited number of 'master' factors is 
sufficient to drive relatively fast and direct specific lineage changes in cells derived 
from different embryonic layers. In effect, lineage conversion is not restricted to the 
same germ layer or lineage, since mesodermal cells like fibroblasts can give rise to 
neurons, which are cells derived from the ectoderm. Furthermore, terminally 
differentiated hepatocytes, derived from the endoderm, were converted into iNs by the 
same neuronal TF (Marro et al., 2011). The generation of iNs seems to follow a 
definite sequence of epigenetic events. In the case of the BAM-mediated 
reprogramming of mouse fibroblasts to iNs, ASCL1 may act as a triggering TF which 
later recruits BRN2 to their binding site, with MYT1L being required at later stages of 
maturation (Wapinski et al., 2013). So, ASCL1 emerged as a master TF that exerts a 
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central role for different neuronal fates depending on the timing of expression and the 
starting cell type. Additional studies have demonstrated that expression of subtype-
specific regulatory factors in human and mouse fibroblasts results in the establishment 
of specific neuronal subtypes, like DA and glutamatergic neurons (See PD and AD 
sections).  
The generation of iNs from nonneural lineages may have significant applications for 
studies of neural development and neurological disease modeling because they can be 
derived from patients. In principle, iNs can be also used for regenerative medicine. 
However, they are not adequate for transplantation treatments (Rhee et al., 2011) 
because, owing to their limited ability to proliferate, only few cells usually survive and 
become functionally integrated to the brain, showing limited effectiveness. In addition, 
because differentiated cells are postmitotic and nondividing, the process of generating 
sufficient numbers of cells for further basic and clinical applications constitutes a 
significant challenge. Within this context, stem and progenitor cells emerge as more 
suitable cell types for obtaining adequate cell stocks and for proper in vivo integration. 
Consequently, a number of studies have focused on the generation of iNSCs, which 
maintain the properties of multipotentiality and self-renewal, and induced neural 
progenitor cells (iNPCs) from fibroblasts by both PDR and LR (Kim et al., 2011b; 
Wang et al., 2012; Ring et al., 2012; Lujan et al., 2012; Han et al., 2012; Thier et al., 
2012). The PDR strategy was used for the first time by Kim et al. (2011b) who 
demonstrated that transient induction of the four Yamanaka pluripotency factors for 3-5 
days followed by appropriate signaling inputs, can efficiently convert fibroblasts into 
functional iNPCs. For example, when EU mouse fibroblasts induced by the OKSM 
reprogramming factors are grown in a medium that contains the neurogenic molecules, 
fibroblast growth factor 2 (FGF2), fibroblast growth factor 4 (FGF4) and epidermal 
growth factor (EGF), colonies of cells showing many of the features of NPCs are 
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generated after 8-9 days in culture. This process is highly efficient and specific, 
requiring only a single step that is completed within 13 days. Compared with iNs, 
iNPCs have the distinct advantage of being expandable in vitro and of retaining the 
ability to give rise to multiple neuronal subtypes and glial cells (Reynolds and Weiss, 
1992). However, the generated populations are usually heterogeneous and the iNPCs 
have shown poor multipotentiality (Kim et al., 2011b). Another group reported the 
direct conversion of human primary fibroblasts into stably expandable iNPCs by timely 
restricted expression of the four Yamanaka factors (Meyer et al., 2015). The generation 
of tripotent iNPCs from adult human fibroblasts by direct reprogramming using OCT4 
alone, was also reported (Mitchell et al., 2014). Because NSCs endogenously express a 
subset of the Yamanaka reprogramming factors, SOX2, KLF4, and c-MYC, but not 
OCT4, Thier et al. (2012) investigated whether curtailed reprogramming with restricted 
OCT4 activity could convert mouse fibroblasts into iNSCs. Those authors demonstrated 
that when the expression of oct4 is selectively repressed after day 5, keeping the other 
three genes overexpressed, colonies of iNSCs are generated. The generation of iNSCs 
from human and mouse fibroblasts by direct reprogramming with a single factor, SOX2, 
was also reported (Ring et al., 2012). The iNSCs express NSC markers and resemble 
endogenous NSC in their morphology, self-renewal ability and gene expression profiles. 
They can differentiate into several types of mature neurons which indicate 
multipotency. Implanted iNSCs survive and integrate in mouse brains and, unlike iPSC-
derived NSCs, they are not tumorigenic. These iNSCs, morover, exhibited, an extensive 
self-renewal capacity as compared with the limited passaging ability of iNPCs (Kim et 
al., 2011b), which could be expanded for only a few passages thus lacking the capacity 
for permanent self-renewal, a critical requirement for clinical applicability. Morover, 
iNPCs apparently lacked the potential to differentiate into oligodendrocytes. Thus, self-
 López-León et al., 2017  18 
 
renewable and multipotent iNSCs devoid of tumorigenic potential may be directly  
generated from fibroblasts by restricted overexpression of pluripotency genes.  
Alternative approaches combined Yamanaka’s factor expression with early neural TF, 
which then help push the EU intermediates into NPCs. In this field, Lujan et al. (2012) 
demonstrated that defined sets of TF highly expressed in NPCs are sufficient to 
transdifferentiate mouse fibroblasts into proliferative iNPCs. Towards this goal, the 
authors started with a set of candidate genes for TF and using stepwise elimination, they 
found that SOX2 and forkhead box protein G1 (FOXG1) are capable of generating self-
renewing bipotent iNPCs, that give rise to astrocytes and functional neurons. When the 
gene for BRN2 was added, tripotent iNPCs were generated which could also be 
differentiated into oligodendrocytes. Furthermore, FOXG1 and BRN2 alone had the 
ability to induce NPC-like cells, which generated less mature neurons, although those 
precursors did produce astrocytes and also oligodendrocytes capable to integrate into 
demyelinated Shiverer mouse brains. However, the resulting population was 
heterogeneous and the issues of contaminating pluripotent SCs persistence with 
teratoma formation after transplantation of iNPCs in animal models, were reported by 
this group (Lujan et al., 2012). 
A similar reprogramming strategy for the direct conversion of fibroblasts into iNSCs 
started with three pluripotency TF together with eight neural specific TF (Han et al., 
2012) and by systematic elimination, the list of effective factors could be reduced to a 
smaller number. Considering that neurogenin 2 (NGN2) and LIM3 are specific for more 
differentiated cell types such as motor neurons (Marro et al., 2011), these factors were 
excluded from the reprogramming cocktail. By this procedure, stable cell lines that 
highly resemble NSCs in morphology, marker gene expression, differentiation potential 
and self-renewing capacity, were successfully generated with two final reprogramming 
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cocktails, a 4-factor or a 5-factor combination (4-factor plus E47). In sum, the authors 
demonstrated that SOX2, c-MYC, KLF4 and BRN4 are active factors sufficient to 
induce transdifferentiation of mouse fibroblasts into iNSCs, in what was a gradual 
process in which the fibroblast transcriptional program was silenced over time. In 
another transdifferentiation approach, Sheng et al. (2012a) demonstrated that Sertoli 
cells which are derived from mesoderm, can be directly converted into iNSC/iNPCs 
expressing multiple NSC-specific markers, exhibiting a global NSC gene-expression 
profile and being capable of self-renewal and differentiating into glia and 
electrophysiologically functional neurons. This was achieved by overexpressing nine 
NSC-specific reprogramming factors. Ectopic expression of the reprogramming genes 
oct4, sox2 and nanog into astrocytes in specific cytokine-containing cultures activated 
the neural stem gene program and generated induced cells expressing neural 
stem/precursor markers (Corti et al., 2012). Figure 3 displays a graphic summary of 
the studies outlined in this section. 
The ectopic expression of brain-enriched miRNAs, miR-9/9* and miR-124 promote the 
direct conversion of human fibroblasts into immature neurons, a process facilitated by 
NEUROD2 (Yoo et al., 2011). The addition of the neurogenic TF ASCL1 and MYT1L 
enhanced the conversion rate and maturation of the converted neurons, whereas 
expression of these TF alone without miRNAs was ineffective. The combination of 
miR-124 with the TF BRN2 and MYT1L can convert adult human fibroblasts into 
functional iNs without the addition of any pioneer TF like ASCL1 (Ambasudhan et al., 
2011). These human iNs exhibit typical marker gene expression,  neuronal morphology, 
fire action potentials, and produce functional synapses between each other. The 
coexpression of miR-9/9*-124 with BCL11B, DLX1, DLX2 and MYT1L (TF highly 
expressed in the developing striatum), can guide the conversion of adult and postnatal 
human fibroblasts into an enriched population of neurons comparable to striatal medium 
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spiny neurons (MSNs) (Richner et al., 2015), a neuronal subpopulation that has a 
crucial role in motor control and displays a selective susceptibility to cell death in 
Huntington’s disease. When transplanted in the mouse brain, the reprogrammed human 
cells persisted in situ for over 6 months, exhibiting membrane properties comparable to 
native MSNs and extended projections to the normal anatomical targets of MSNs 
(Victor et al., 2014). 
Because this direct conversion bypasses pluripotent/multipotent stem cell stages, 
miRNA-mediated directly reprogrammed neurons would retain the age signature of the 
original donor. Using a miRNA-based cellular reprogramming approach, human 
fibroblasts obtained from donors ranging from neonates to near centenarians can be 
efficiently converted into neurons that retain multiple age-associated signatures (Huh et 
al., 2016). To assess cellular age, Huh et al. (2016) used the epigenetic clock method, 
considered to be a highly accurate biomarker of age based on DNA methylation 
(Horvath , 2013). They evaluated age-associated signatures based on the level of gene 
expression, miRNAs, and cellular readouts considered to be hallmarks of aging (López-
Otín et al., 2013) to finally demonstrate the maintenance of the age of the original 
donor cells during neuronal conversion. These directly converted human neurons can be 
advantageous for studying age-related neuronal disorders, while iPSC-derived cells are 
unsuitable in recapitulating phenotypes specifically observed in aged cells (Mattson 
and Magnus, 2006; Vera and Studer, 2015). As mentioned above, induction of 
pluripotency in adult fibroblasts reverts cellular age to an embryonic stage erasing the 
epigenetic marks of aging (Lapasset et al., 2011; Patterson et al., 2012). This feature 
(youth) remains so even after neuronal differentiation (Miller et al., 2013). 
4.1 Generation of neural cells by non-integrative direct cell reprogramming 
strategies 
 López-León et al., 2017  21 
 
The clinical applications of iNs or their precursors are strongly compromised in most of 
the reprogramming strategies by the fact that they involve integrative gene transfer with 
the well-known risk of gene silencing or insertional mutagenesis. We hypothesize that 
adenoviral vectors constitute a safer reprogramming alternative and have thus, designed 
a regulatable bidirectional helper-dependent adenovector expressing the four OKSM 
pluripotency genes as well as the gene for humanized green fluorescent protein (hGFP) 
which should allow us to implement a direct reprogramming protocol in a non-
integrative fashion in order to generate fibroblast-derived iNPCs and terminally 
differentiated neurons (López-León et al., 2014). In order to overcome the lower 
transduction efficiency of adenovectors as compared to retroviral vectors, we can use 
the magnetofection technique during cell reprogramming. Magnetofection is based on 
complexing adenoviral vectors to magnetic nanoparticles which under the influence of a 
magnetic field, efficiently enter the target cells. This procedure markedly increases the 
transduction efficiency of adenovectors in cell culture (Schwerdt et al., 2012). 
Alternative integration-free strategies for direct reprogramming including plasmid 
vectors, targeted gene repression by miRNA or small molecules, have been explored.  
The generation of integration-free iNSCs from mouse fibroblasts by nonviral episomal 
vectors containing the genes for the TF BRN4, SOX2, KLF4 and c-MYC has recently 
been reported (Kim et al., 2016). The episomal vector-derived iNSCs closely resemble 
control NSCs and iNSCs generated by retrovirus in morphology, gene expression 
profile, epigenetic status, and self-renewal capacity. Furthermore, the episomal vector-
derived iNSCs are functionally mature, as they could differentiate into all the neuronal 
cell types in vivo as well as in vitro. Another study established a vector-mediated 
reprogramming protocol based on the expression of OCT3/4, SOX2, KLF4, L-MYC, 
Lin28 and a small hairpin RNA directed against p53 (sh-p53). In order to obtain iNSCs 
from adult human fibroblasts a defined culture medium in combination with the 
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neurotrophins bFGF, EGF and FGF4 was used after transduction. The cultivation was 
performed without the addition of small molecules (Capetian et al., 2016).  
Finally, the successful generation of iNs from human and mouse fibroblasts by chemical 
approaches was achieved by identifying optimal cocktails of small molecules without 
needing additional genetic factors. In effect, Li et al.(2015) showed that 4 small 
molecules (Forskolin, N-cyclopropyl-5-(2-thienyl)-3-isoxazolecarboxamide (ISX9), the 
glycogen-synthetase inhibitor CHIR99021 and the bromodomain-protein inhibitor  I-
BET151) were enough for mouse fibroblast conversion to iNs. Hu et al. (2015) reported 
that human fibroblasts could be converted into neurons using a cocktail of small 
molecules (valproic acid (VPA), CHIR99021, the kinase inhibitor RepSox, Forskolin, 
the anthrapyrazolone kinase inhibitor (SP600125), the protein-kinase inhibitors 
GO6983 and Y-27631, and the AMP-kinase inhibitor dorsomorphin) as could 
fibroblasts from familial AD patients. These iNs can be used for in vitro disease 
modeling and drug screening. Interestingly, it was shown that the sequential addition of 
a cocktail of small molecules -the bone-morphogenic-protein–receptor inhibitor 
LDN193189, the activin-receptor-like kinase inhibitor SB431542, the retinoic-acid 
analogue TTNPB, the protein-kinase inhibitor thiazovivin, CHIR99021, VPA, the γ-
secretase inhibitor DAPT, the smoothened-protein agonist SAG and the hedgehog-
signalling–pathway inhibitor Purmorphamine- which inhibit glial- but activate neuronal 
signaling pathways through epigenetic and transcriptional modulation, can reprogram 
human astrocytes into functional neurons (Zhang et al., 2015). These human iNs could 
survive more than 5 months under cell culture conditions. 
Small molecule-mediated reprogramming was also reported for generation of iNSCs. 
Thus, a novel chemical cocktail-comprised of the activin-receptor-like–kinase inhibitor 
A83-01, CHIR99021, sodium borate (NaB [sic]), lysophosphatidic acid (LPA), the 
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cyclic-AMP–phosphodiesterase inhibitor Rolipram and SP600125, enabled the 
generation of expandable human iNSCs from fibroblasts transduced with OCT4 alone 
(Zhu et al., 2014). In the same year, Cheng and colleagues used three small molecules, 
VPA -CHIR99021 and RepSox- to induce NPCs from somatic cells (Cheng et al., 
2014). More recently, a cocktail of nine components -CHIR99021, LDN193189, A83-
01, retinoic acid, another smoothened-protein agonist, HhAg1.5, the DNA-
methyltransferase inhibitor  RG108,  the monoamine-oxidase inhibitor Parnate™ 
(tranylcypromine), the mammalian-autophagy inducer 6-bromo-N-2-propenyl-4-
quinazolinamine (SMER28) and bFGF- was used to generate iNSCs from mouse 
fibroblasts in a more efficient approach (Zhang et al., 2016a).  
4.2 Advances in in vivo reprogramming for neural regeneration 
Recent advances suggest that direct in vivo reprogramming of endogenous cell 
populations may provide a promising prospect for cell-based clinical regenerative 
therapy through neuron replacement (Chen et al., 2015; Li and Chen, 2016). Glial 
cells constitute the most abundant cells in adult brains and several groups have reported 
the successful TF-based in vivo reprogramming of glial cells to neurons or iNPCs. 
Astrocytes appear as the natural in vivo cell target to reprogram into neuronal cells not 
only because of the capacity of those glial cells to become reactive after damage or 
neurodegeneration and their abundance in the CNS, but also because a series of in vitro 
studies demonstrated their direct conversion into functional iNs. The overexpression of 
the TFs PAX6, NEUROG2, ASCL1 or DLX2 can convert astroglia from the early 
postnatal cortex to functional iNs by LR (Berninger et al., 2007; Heinrich et al., 2010; 
Heins et al., 2002). As mentioned above the feasibility of directly reprogramming 
astrocytes into iNSCs and iNs by overexpression of OCT4, SOX2 and NANOG, has 
been also demonstrated (Corti et al., 2012). The feasibility of converting resident 
 López-León et al., 2017  24 
 
astrocytes directly into neural cells in the adult brain in vivo was assessed. Endogenous 
astrocytes can be reprogrammed to proliferating neuroblasts by delivering SOX2 (Niu 
et al., 2013) and thereafter can be further differentiated to functional neurons that 
integrate into neural networks in the brain. It was subsequently shown that astrocytes 
can be reprogrammed into neurons with SOX2, within the context of adult spinal cord 
injury (Su et al., 2014). Guo et al., (2014) demonstrated that cortical glial cells activated 
by injury or disease could be reprogrammed in vivo by NEUROD1 into functional 
neurons. Torper et al. (2013) furthermore showed that astroglia can be reprogrammed in 
vivo into neurons in the adult brain by overexpression of the TFs, ASCL1, BRN2 and 
MYT1L. 
Another study demonstrates that a single, nontoxic adeno-associated viral vector can 
reprogram striatal oligodendrocytes in vivo, such that they transdifferentiate into 
functional neurons (Weinberg et al., 2017). A key feature of this reprogramming 
approach involves the ability to preferentially targeting oligodendrocytes in vivo in the 
rat striatum and the cell-specific suppression of polypyrimidine tract-binding (PTB) 
protein expression. Xue et al. (2013) reported that suppression of PTB protein 
expression in cultured mouse embryonic fibroblasts caused their differentiation into 
functional, NeuN-positive neurons. 
An electrochemical method of gene delivery in vivo to rapidly manipulate gene 
expression specifically in postmitotic neurons has been developed. With this technique, 
mouse spiny neurons were specifically reprogrammed during the first postnatal week by 
ectopic expression of the layer 5B output neuron-specific TF, Fezf2 (De la Rossa et al., 
2013). These findings suggest that the identity of postmitotic neurons can be 
reprogrammed in vivo long after they are born. These postmitotic neurons exhibit a high 
level of functional plasticity in which transcriptional programs can be activated so that 
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they fundamentally reassign their morphology, physiological properties and circuit 
identity in a coordinated and functionally meaningful manner. In closing the section a 
brief comparison between in vivo and in vitro reprogramming is in order. A major 
advantage of in vivo cell reprogramming is that it uses resident brain cells, mainly 
astrocytes, to generate specific neuronal cell populations. This strategy avoids the risk 
of contamination of the induced neural cells with exogenous components like, for 
instance, those coming from MEF co-cultures and ensures the fidelity of the neuronal 
cells generated. In more general terms, neural cells generated by in vivo reprogramming 
are never exposed to in vitro environments and are therefore less likely to acquire non-
physiologic features. Furthermore, the therapeutic effects of in vivo reprogramming can 
be readily assessed in the experimental animals. As a counterbalance to these 
advantages the in vivo delivery of reprogramming TF is much less efficient than 
delivery in vitro. Thus, the risk of attaining therapeutically insufficient numbers of 
induced neural cells is a concern. With in vitro reprogramming the opposite occurs. 
Furthermore, in vitro reprogramming is technically less challenging and the 
reprogrammed cells are easier to characterize. However, the therapeutic effectiveness of 
the new cells needs to be subsequently checked in vivo.   
 
5. REGENERATIVE MEDICINE FOR THE AGING BRAIN 
5.1 Therapeutic potential of cell reprogramming for PD 
The advent of cell reprogramming techniques has enabled PD researchers to derive 
iPSCs as well as iNs and iNSC/iNPCs from easily accessible somatic cells from 
patients. Currently, DA neurons can be derived through differentiation from iPSCs 
(Wernig et al., 2008) and by direct conversion from fibroblasts (Kim et al., 2011a;  
Pfisterer et al., 2011; Rhee et al., 2011; Caiazzo et al., 2011;  Liu et al., 2012b).  
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DA neurons derived from ESCs have proved to be functional when grafted into 
parkinsonian rats (Kriks et al., 2011; Kim et al., 2002). This enabled the differentiation 
of mouse iPSCs  into DA neurons in order to evaluate their therapeutic potential in a rat 
model of PD (Wernig et al. 2008). After treatment of iPSC-derived neural precursor 
cells with sonic hedgehog (SHH) and FGF8, most cells differentiated into a βIII-
tubulin-positive phenotype with neuronal morphology, which showed markers typically 
expressed in midbrain DA neurons. They demonstrated functional recovery of 
parkinsonian rats after cell transplantation. Since teratoma formation after 
transplantation seems to be a frequent complication for cell therapy, fluorescence-
activated cell sorting (FACS) was used to eliminate the undifferentiated cell fraction. 
No tumor formation was observed after 8 weeks of transplantation whereas the animals 
exhibited a similar recovery rate in a behavioral test compared with animals receiving 
unsorted cells. This study revealed that iPSC-derived DA neurons display synaptic 
integration and dopaminergic function after transplantation into the adult brain in a rat 
model of PD.  
More recently, derivation of human DA neurons from iPSCs was achieved (Kriks et 
al., 2011). Midbrain precursors were derived from human iPSCs and exposed to SHH 
and canonical WNT signaling. After 25 days, transdifferentiated induced DA (iDA) 
neurons were observed. These cells exhibited molecular, biochemical and 
electrophysiologic profiles which confirm their cell identity and could be maintained in 
vitro for several months. The study demonstrated in vivo survival and function of 
human iDA neurons in three PD animal models. Thus, in 6-OHDA-lesioned mice and 
rats, the cells showed robust survival, improvements in tests of akinesia and complete 
restoration of amphetamine-induced rotation behavior. The excellent cell survival, 
function and scalability demonstrated by transplantation into parkinsonian monkeys, 
reveal a significant potential for implementation of cell therapies in PD patients. 
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In a direct approach using a combination of the TFs ASCLI, NURR1 and LMX1A, 
functional iDA neurons from mouse and human fibroblasts were generated without 
passing through a progenitor cell stage (Caiazzo et al., 2011). This study also indicated 
that DA neurons can be generated from the cells of patients with PD. More recently, the 
efficiency of reprogramming human cells to iDA neurons via the 
ASCL1/NURR1/LMX1A combination was greatly improved by addition of the small 
noncoding miR-124 plus a cocktail of neurotrophic factors and small molecules (Jiang 
et al., 2015). The efficiency was additionally improved to derive TH+/TUJ1+ neurons 
from human fetal fibroblasts, with the iDA neurons so generated expressing the DA 
markers AADC, ALDH, DAT, VMAT2, PITX3, NURR1, FOXA2 and EN 1. The 
highest conversion efficiency (60% yield) was achieved with human fetal fibroblasts but 
dropped progressively as the age of the fibroblast donor increased, being 16%, 11% and 
8% when the donor age in years, was 0 (i.e., newborn), 31 and 96, respectively (Jiang 
et al., 2015).  
Another study demonstrated that a combination of the TFs, ASCLI and NURR1, along 
with neurotrophic factors like SHH and FGF8B, transdifferentiated embryonic mouse 
fibroblasts to iNs, including DA neurons and pan-neuronal cells (Oh et al., 2014). A 
combination of the nine genes ascl1, ngn2, hes1, id1, pax6, brn2, myc, klf4 and sox2, 
was shown to reprogram mouse fetal and postnatal fibroblasts into iNs, 10% of which 
expressed TH as well as EN1 and PITX3 (Sheng et al., 2012b). Differentiation of rat 
embryonic fibroblast-derived iNPCs into functional DA neurons was enhanced by 
overexpression of NURR1 and FOXA2, yielding up to 40% TH+ cells (Lim et al., 
2015). The generation of 90% TH+/TUJ1 neurons from adult mouse fibroblast-derived 
iNPCs generated by overexpression of brn2, sox2 and foxa2, with or without exposure 
to SHH and FGF8, was also reported (Tian et al., 2015). 
 López-León et al., 2017  28 
 
As to studies with induced neuronal cells in animal models of PD, it has been reported 
that iPSCs can be induced to differentiate into DA neurons and be subsequently 
implanted into the brain of rat models of PD where they are able to improve behavior 
(Politis and Lindvall, 2012). These DA neurons have been reported to synaptically 
integrate into fetal brain and function into the adult brain after transplantation in a rat 
model of PD (Wernig et al., 2008). In another study employing parkinsonian 
cynomolgus monkeys (CM), iPSC-derived midbrain DA neurons survived for up to 2 
years following autologous transplantation. In one of the animals with a highly 
successful protocol, unilateral engraftment of CM-iPSCs-derived midbrain DA neurons  
induced a progressive improvement of motor function contralateral to the side of DA 
neuron transplantation, and increased motor activity, without a need for 
immunosuppression. Postmortem analyses showed robust survival of midbrain-like DA 
neurons and extensive outgrowth into the transplanted putamen (Hallett et al., 2015; 
Kriks et al., 2011).  
Another study reported that iNSCs per se have therapeutic effects in a PD mouse model 
(Wu et al., 2015). Furthermore, the study revealed that iNSCs engineered to 
overexpress the TF LMX1A (iNSC-LMX1A), can further enhance the therapeutic 
efficacy of iNSCs when transplanted into a mouse model of PD. It was found that 
iNSC-LMX1A give rise to an increased yield of DA neurons and higher levels of 
dopamine in vitro, when compared with control iNSCs that express GFP (iNSCs-GFP). 
When iNSCs-GFP and iNSCs-LMX1A were transplanted into PD mice, both groups 
showed decreased ipsilateral rotations; yet, mice that received iNSCs-LMX1A exhibited 
better recovery than mice that received iNSCs-GFP. This study demonstrated for the 
first time that iNSCs directly converted from somatic cells exert therapeutic effects 
when transplanted into mouse PD models. Considering that LMX1A plays a central role 
in the specification of DA neurons (Deng et al., 2011; Andersson et al., 2006), the 
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above results suggest that this TF could be employed as an enhancing factor for 
differentiation of iNSCs into DA neurons. More recently, a fully defined feeder- and 
xenogeneic-free protocol for the generation of ventral midbrain dopamine (vmDA) 
neurons from hPSCs has been reported. It utilizes two reporter knock-in lines (LMX1A-
eGFP and PITX3-eGFP) for in vitro and in vivo tracking. Across multiple embryonic 
and induced hPSC lines, this protocol consistently increased both the yield and 
proportion of vmDA neural progenitors (OTX2/FOXA2/LMX1A) and neurons 
(FOXA2/TH/PITX3) that display classic vmDA metabolic and electrophysiologic 
properties (Niclis et al., 2017).  
It should be pointed out however, that NSCs seem more likely to differentiate into glia 
than into functional neurons after transplantation (Holmin et al., 1997; Johansson et 
al., 1999), which is a disadvantage for neuron-replacement therapy for PD and other 
neurodegenerative diseases. An interesting alternative is offered by the fact that DA 
progenitors (DAPs) can be generated under appropriately modified environmental 
conditions by a PDR strategy similar to that used to generate iNSCs (Kim et al., 
2011b). Although these DAPs are more committed than NSCs, the former are still not 
terminally differentiated neurons. More recently, Kim et al. (2014) showed that mouse 
fibroblasts can be directly reprogrammed into midbrain DAPs by transient (5 days) 
expression of the four Yamanaka genes and subsequent exposure (for 8 days) to SHH 
and FGF8. Within thirteen days, self-renewing and functional induced DAPs were 
generated. Interestingly, the inhibition of both the tyrosine kinase Jak and the glycogen-
synthase kinase Gsk3β notably enhanced the reprogramming efficiency. This study 
demonstrated the feasibility of inducing a specific cell type, switching from fibroblasts 
to specific DAPs through a PDR strategy.  
Although direct reprogramming approaches hold much promise for the treatment of PD, 
so far direct reprogramming of human cells to authentic ventral midbrain dopaminergic 
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(vmDA) neurons has not been documented. In contrast, a number of alternative 
strategies exist, not to be reviewed here, to generate human vmDA neurons by 
patterning embryoid bodies expressing the TF PAX6 or by floor-plate patterning 
(Playne and Connor, 2017). 
 
5.2 Therapeutic potential of cell reprogramming for AD 
Stem cell therapy for AD has been attempted with adult cells and ESCs as well as with 
iPSC (Lee et al., 2016). Here, we will focus on the potential of induced neural cells for 
the treatment of AD in patients and AD animal models.  
Since the initial stages of AD are characterized by an early loss of basal forebrain 
cholinergic neurons (BFCN), cholinergic neuron replacement appears as a relevant 
therapeutic goal. Within this context, it is of interest that BFCN can be consistently 
derived from human ESCs (Bissonnette et al., 2011) and possibly from human iPSCs. 
It has been also demonstrated that functional glutamatergic neurons can be generated by 
reprogramming skin fibroblasts from normal individuals and familiar AD patients by 
overexpression of a larger set of forebrain transcription regulators (BRN2, MYT1L, 
ZIC1, OLIG2 and ASCL1) in the presence of neuronal survival factors (Qiang et al., 
2011). In a different strategy, two small molecules, forskolin and dorsomorphin were 
used to enable the TF Neurogenin 2 (NGN2) to directly convert human fetal lung 
fibroblasts into cholinergic neurons with a high level of purity (>90%) and efficiency 
(up to 99% of NGN2-expressing cells), thus bypassing any pluripotency stage. The 
induced human cholinergic neurons displayed mature electrophysiologic properties and 
exhibited motor neuron-like features. Inclusion of an additional TF, SOX11, allowed an 
efficient conversion of postnatal and adult skin fibroblasts from healthy individuals and 
AD patients into cholinergic neurons (Liu et al., 2013). Using a transgene-free 
approach, Hu et al. (2015) were able to convert human fibroblasts from normal and AD 
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subjects into iNs. The authors used a chemical cocktail of seven small molecules, 
referred to as VCRFSGY, namely, valproic acid, CHIR99021, Repsox, Forskolin, 
SP600125 (an inhibitor of the N-terminal kinase JNK), GO6983, (a protein-kinase-C 
inhibitor, G) and Y-27632 (ROCK inhibitor, Y; cf. Section 4.1) which directly 
converted fibroblasts into neurons bypassing the neural progenitor stage. The 
chemically-induced human neurons resembled hiPSC-derived neurons and human iNs 
with respect to morphology, gene expression profiles, and electrophysiologic properties. 
This approach provides an alternative strategy for modeling neurological diseases and 
for regenerative medicine. Another promising type of cells for the treatment of AD are 
the neural restricted progenitor (NRP), which represents a type of transitional 
intermediate lying between the multipotent NPC and terminally differentiated neuron 
generated during normal neurogenesis. Neural restricted progenitors have the ability of 
self-renewal and migration in the nervous system (Mayer-Proschel et al., 1997; Yang 
et al., 2000) and can differentiate into neurons rather than glial cells in vivo and in vitro 
(Mo et al., 2007; Mujtaba et al., 1999). When injected into the rodent subventricular 
zone, NRPs can migrate extensively, integrate into different regions of the brain and 
differentiate into various neuronal subtypes, thus contributing to brain plasticity and 
repair (Yang et al., 2000). Although NRPs appear to be well-suited for cell therapy of 
AD, it is difficult to obtain highly purified NRPs from normal nervous tissue (Mayer-
Proschel et al., 1997; Kalyani et al., 1998), which prevents further studies and 
applications that require relatively large number of cells. Hope has now arisen, however 
that this limitation may be overcome by cell reprogramming. In effect, it was recently 
demonstrated that by using only three defined TFs -SOX2, c-MYC and either BRN2 or 
BRN4- human fetal fibroblasts can be converted into human induced NRPs (hiNRPs) 
(Zou et al., 2014). These hiNRPs display self-renewal capacity and exhibit distinct 
neuronal characteristics including the expression of multiple neuronal markers, a 
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neuronal genome-wide transcriptional profile and neuron-like morphology. These 
hiNRPs can be differentiated into various terminal neuron subtypes with functional 
membrane properties, but not into glial cells. Thus, a direct and highly efficient 
conversion of somatic cells into hiNRPs may provide a new source of cells for neuronal 
development studies as well as for cell replacement therapy of AD patients. 
Cell reprogramming is also being used for disease modeling in AD patient-derived 
iPSCs (Zhang et al., 2016b). Familial AD patient-derived iPSCs were first established 
by Yagi et al. (2011) who confirmed that the production of highly toxic Aβ42 peptide is 
enhanced in all patient-specific iPSC lines. In addition, iPSC-derived neurons carrying 
mutations respond sharply to γ-secretase modulators and inhibitors, indicating that 
neurons derived from patient-specific iPSCs hold a significant potential in AD drug 
discovery. In a gene expression study in iPSC-derived neurons from a 82-year-old 
sporadic AD patient, significant gene expression changes were observed between 
primary cells and induced neurons (Hossini et al., 2015). In another study, iPSC-
derived neurons were generated from individuals with sporadic or familial AD, the 
latter caused by duplication of the gene encoding the amyloiod-precursor protein APP, 
and were shown to produce significantly higher Aβ40 levels. The study also 
demonstrated other key pathologic features of AD-iPSC-derived neurons, including an 
increase of phosphorylated tau and of its kinase (GSK) activity (Israel et al., 2012). 
Evidence has also been found that neurons derived from AD iPSCs exhibit increased 
vulnerability to glutamate-mediated cell death (Duan et al., 2014) and that the 
accumulation of amyloid beta (Aβ) oligomers induce oxidative stress leading to 
apoptosis (Kondo et al., 2013; Nishitsuji et al., 2009). Neural cells derived from a 
sporadic AD patient and from another patient carrying the pathogenic APP-E693D 
mutation, produced intracellular accumulation of Aβ oligomers (Kondo et al., 2013).   
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When human iPSC-derived macrophage-like cells (iPSC-ML) expressing the Aβ 
proteolitic enzyme Neprilysin-2 (NEP2) and the Fc-receptor-fused form of a single 
chain antibody specific to Aβ (termed iPS-ML/NEP2 cells), were administered 
intracerebrally to 5XFAD mice, a model of AD, a significant reduction in the level of 
Aβ in the brain interstitial fluid was observed. The authors conclude that iPSC-
ML/NEP2 cells may be a potential therapeutic agent in the treatment of AD 
(Takamatsu et al., 2014). In an interesting study, human APP transgenic mice, which 
display progressive amyloid β deposition and at 8 weeks of age show significant deficits 
in spatial memory, were bilaterally transplanted in the hippocampus with neuronal 
precursors of cholinergic neuron phenotype that were derived from human iPSCs. After 
receiving the cell implants, the transgenic APP mice displayed a significant 
improvement in spatial memory performance as compared with untreated counterparts. 
Forty-five days after neural precursor cell transplantation choline acetyltransferase 
positive cholinergic human neurons and GABA vesicle-transporter-positive GABAergic 
human neurons were detected in the hippocampus of the APP mice (Fujiwara et al., 
2013).  
 
6. CONCLUDING REMARKS 
Neurodegenerative diseases are intractable neurologic disorders that constitute a 
problem of growing medical and economic impact. Within this context, the 
development of novel therapeutic approaches like regenerative medicine may open new 
avenues for the treatment of brain disorders. In recent years, cell reprogramming has 
emerged as a powerful technology that promises to make possible the implementation 
of regenerative medicine for, up to now, incurable neurodegenerative diseases. It seems 
therefore plausible to hypothesize that in the not-too-distant future a mature cell 
reprogramming technology will provide effective means for treating these devastating 
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brain pathologies. A different path to deal with age-related brain disorders comes from 
the emerging evidence suggesting that rejuvenating a full organism by partial cell 
reprogramming may be achievable in the near future. Such an approach promises to 
provide humankind with the ultimate therapeutic intervention for age-related (and other) 
brain pathologies, rejuvenation.  
The data reviewed here reveal that neural cell generation in vitro and to a lesser extent, 
in vivo, are fast growing fields of research whose ultimate goal is to establish effective 
protocols to produce substantial stocks of patient-derived neural cells, particularly, 
iNSC and iNPC that can be safely used for the treatment of PD, AD and other brain 
pathologies. While the use of direct reprogramming strategies is gaining ground, iPSC 
technology still remains as the main source of induced neural cells. Although the use of 
neural cells derived from somatic cells from the patient remains as an attractive 
possibility for implementing personalized regenerative medicine in the brain, the time  
taken to generate patient-derived neural cells from somatic cells constitutes a significant 
limitation for the routinely use of this approach in AD and PD. An alternative strategy 
that is being considered in reference to brain and other pathologies is the creation of 
banks of induced cells, which like blood banks, would be far more practical and cost-
effective than personalized approaches.     
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FIGURE LEGENDS 
Figure1. Diagrammatic representation of the epigenetic changes that occur in 
chromatin during aging and induced–pluripotent-stem-cell (iPSC) generation. The 
upper diagram represents some of the progressive changes in histone H3 and H4 
methylation and acetylation as well as DNA methylation during normal aging.  The 
lower diagram represents the chronologic changes that may occur on the same 
epigenetic marks during pluripotency-factor induced rejuvenation/dedifferentiation. Red 
symbols represent chromatin activating marks whereas black symbols correspond to 
chromatin repressor marks. Stemmed stars represent DNA methylation marks. Blue 
wavy lines represent gene transcripts (RNAs). The key below the figure describes the 
above-mentioned symbols.    
 
Figure 2. Diagrammatic representation of the different cell reprogramming 
methods currently being used. Diagram A illustrates the conventional iPSC-
mediated protocol of cell reprogramming where somatic cells are first dedifferentiated 
to iPSC which in turn are differentiated into the induced target somatic cell. Diagram B 
represents the reprogramming procedures termed lineage reprogramming also called 
transdifferentiation. These procedures are based on the overexpression of cell-type 
specific genes and bypass the pluripotency stage. Unlike iPSC-mediated strategies, 
transdifferentiation does not seem to erase epigenetic marks of aging. Diagram C 
outlines direct reprograming strategies called pluripotency-mediated direct 
reprogramming (PDR) which are based on the transient overexpression of the four 
Yamanaka genes in somatic cells that become pluripotent intermediates (PI) which are 
responsive to specific differentiation cocktails that can take them to the desired induced 
somatic cell type. The rejuvenated cells are represented in blue color, the 
nonrejuvenated cells in brown.   
 
Figure 3. Diagrammatic summary of the cell reprogramming reports on the 
generation of induced neurons (iNs), induced neural progenitor cells (iNPCs) and 
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induced neural stem cells (iNSCs). Diagram A summarizes the iPSC-mediated 
strategies, Diagram B represents the LR approaches, Diagram C illustrates PDR 
strategies and Diagram D recapitulates approaches using pluripotency genes (PDR) 
plus lineage-specific transcription factors. Somatic cell types of origin include skin and 
lung fibroblasts, glia, hepatocytes and Sertoli cells and are shown in brown color. 
Pluripotent and rejuvenated cells as well as the pluripotent intermediates (PIs) and 
iPSCs are indicated in blue. Induced neurons (iNs) are either rejuvenated or 
nonrejuvenated according to the reprogramming strategy used. Thus, the brown and 
blue portions of the iN shown in the figure represent the proportion of rejuvenated and 
nonrejuvenatd cells resulting from the different reprogramming stategies used to 
generate them. Brown reference columns correspond to integrative in vitro cell 
reprogramming approaches reported in the indicated year. Red columns indicate 
references to integration-free approaches. Green columns list in vivo approaches 
reported. The numbered references in the figure are:(1) Takahashi and Yamanaka, 2006; 
(2) Vierbuchen et al., 2010; (3) Pang et al., 2011; (4) Ambasudhan et al., 2011; (5) 
Marro et al., 2011; (6) Sheng et al., 2012; (7) Kim et al., 2011b; (8) Thier et al., 2012; 
(9) Ring et al., 2012; (10) Mitchell et al., 2014; (11) Meyer et al., 2015; (12) Lujan et 
al., 2012; (13) Han et al., 2012; (14) Kim et al., 2016; (15) Capetian et al., 2016; (16) 
Corti et al., 2012; (17) Niu et al., 2013; (18) Su et al., 2014; (19) Heins et al., 2002; 
(20) Berninger et al., 2007; (21) Heinrich et al., 2010; (22) Torper et al., 2013; (23) Gu 
et al., 2014. 



 López-León et al., 2017  51 
 
Table 1. Cell reprogramming studies related to PD 
Approach TF used In vitro / in vivo Results References 
LR Ascl1, Brn2, and Myt1l Conversion of human embryonic and postnatal 
fibroblasts to DA neurons.  
Pfisterer et al., 2011 
iPSC hiPSC generated by direct delivery 
of arginine-tagged OKSM proteins 
(Pro-1 and Pro-2) 
hiPSC were differentiated into NPC and DA 
neurons by exposure to bFGF and  SHH and 
FGF8.  
Rhee et al., 2011 
LR Mash1, Ngn2, Sox2, Nurr1, and 
Pitx3 
Reprogramming of human fibroblasts into DA 
neuron-like cells. 
Liu et al., 2012 
LR AsclI, Nurr1 and Lmx1a functional DA neurons from mouse and human 
fibroblasts 
Caiazzo et al., 2011 
LR ASCL1/NURR1/LMX1A+miR124 
plus a cocktail of neurotrophic 
factors and small molecules 
human fibroblasts from fetal to 91y old donors to 
iDA neurons 
Jiang et al., 2015 
LR ASCLI and NURR1 plus SHH and 
FGF8B, transdifferentiated cells to 
iNs, including DA neurons. 
embryonic mouse fibroblasts to iNs (DA plus pan-
neuronal cells) 
Oh et al., 2014 
LR ascl1, ngn2, hes1, id1, pax6, brn2, 
myc, klf4 and sox2, 
Reprogramming of mouse fetal and post-natal 
fibroblasts into iNs, 10% of which express TH. 
Sheng et al., 2013 
LR NURR1 and FOXA2 Ribroblast-derived iNPCs were differentiated into 
functional DA neurons. 
Lim et al., 2015 
LR brn2, sox2, foxa2 and l-myc with or 
without exposure to SHH and 
FGF8 
Generation of 90% TH+/TUJ1 neurons from adult 
mouse fibroblast-derived iNPCs. 
Tian et al., 2015 
iPSC SHH and FGF8 iPSC-derived NPC were differentiated into DA 
neurons and other neuron types. 
Wernig et al., 2008 
iPSC Retinoic acid, SSH and FGF8a Differentiation of iPSC into ventral midbrain 
dopaminergic neurons. 
Hallett et al., 2015 
LR Pax6, Ngn2, Hes1, Id1, Ascl1, 
Brn2, Sox2, c-Myc to induce 
iNPC. 
SAG and FGF8, followed by 
BDNF and AA was subsequently 
used to differentiate iNPC-Lmx1a 
to DA neurons. 
TT mouse fibriblasts were reprogrammed to iNPC 
which were later transduced with a  Nestin-Lmx1a 
lentivirus and differentiated into DA neurons  
Wu et al., 2015 
PDR OKSM genes (for 5 days) followed 
by SHH and FGF8 (8 days).    
Inhibition Jak and Gsk3β enhanced 
reprogramming efficiency. 
Mouse fibroblasts directly reprogrammed into 
midbrain DA precursors (DAPs).  
Kim et al., 2014. 
 
Abbreviations: hiPSC, human induced pluripotent stem cell. DA, dopamine (ergic); 
SSH, sonic hedgehog; FGF8, fibroblast growth factor 8; TH, tyrosine hydroxylase; 
iNPC, induced neural progenitor cell; DAP, dopaminergic progenitor cell. 
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Table 2. Cell reprogramming studies related to AD 
Cell Source Approach TF used In vitro / in vivo Results Reference 
skin fibroblasts 
from normal 
individuals and 
familiar AD 
patients 
LR (lineage-
specific TF) 
Brn2, Myt1l, 
Zic1, Olig2 and 
Ascl1  
functional glutamatergic neurons (or… induced 
neuronal cells which display morphological, 
electrophysiological, and gene expression 
profiles that typify glutamatergic forebrain 
neurons) 
Qiang et al., 
2011 
human fetal lung 
fibroblasts 
Small molecules + 
lineage-specific TF 
NGN2 + 
forskolin, 
dorsomorphin 
cholinergic neurons Liu et al., 
2013 
post natal and adult 
skin fibroblasts 
from healthy 
individuals and AD 
patients  
Small molecules + 
lineage-specific TF 
NGN2, SOX11 
+ forskolin, 
dorsomorphin 
cholinergic neurons  Liu et al., 
2013 
human fetal 
fibroblasts  
PDR + lineage-
specific TF 
SOX2, c-MYC, 
BRN2/BRN4 
human induced neural restricted progenitors 
(NRPs) 
Zou et al., 
2014 
familial AD-
patient derived 
iPSCs 
Differentiation  - 
iPSC-derived neurons carrying mutations with 
increased amyloid β42 secretion that respond to 
γ-secretase inhibitors and modulators 
Yagi et al., 
2011 
Miura et al., 
2009 
sporadic AD 
patient-derived 
iPSCs 
Differentiation  - iPSC-derived neurons expressing p-tau and 
GSK3 which respond to γ-secretase inhibitors 
Hossini et 
al.,2015 
sporadic and 
familial AD 
patient-derived 
iPSCs 
Differentiation  - 
iPSC-derived neurons that produce significantly 
higher Aβ40 levels, increase of phosphorylated 
tau and of its kinase (GSK) activity 
Israelet al., 
2012 
sporadic and 
familial AD 
patient-derived 
iPSCs 
Differentiation  - iPSC-derived neurons with Aβ oligomers 
intracellular accumulation 
Kondo et al., 
2013 
human iPSCs Differentiation (4*) - 
iPSC-derived macrophage-like cells (iPSC-ML) 
which reduced the level of Aβ added to the 
culture medium, and the culture supernatant of 
iPSC-ML alleviated the neurotoxicity of Aβ. 
iPSC-ML expressing NEP2 i.c.v. administered 
in a mouse model of AD produced a significant 
reduction in the level of Aβ in the brain 
interstitial fluid  
Takamatsu et 
al., 2014 
human iPSCs 
Differentiation by 
culturing iPSCs 
with retinoic acid, 
SHH and noggin-Fc 
- 
neuronal precursors with cholinergic neuron 
phenotype transplanted into bilateral 
hippocampus of PDAPP mice model of AD, 
significantly improved spatial memory 
dysfunction and survived for 45 days after 
transplantation 
Fujiwaraet al., 
2013 
 
 
References to Table s1 and 2 are located on the reference list at the end of the article.  
